ClinicalTrials.gg

Program

EYU688

A development code.

In Novartis's pipeline, NS4B inhibitor. Its studies are mostly in Dengue, led by Novartis.

Furthest: phase 2, since Aug 17, 20231 company-led study, 1 open or runningNext primary completion: Jul 22, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis11 open or runningphase 2since Aug 17, 2023Aug 17, 2023Jul 22, 2027phase 2 · NCT06006559
  • Named in Novartis’s own pipeline as EYU688, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 17, 2023First study: phase 2 study in DengueFirst studyNCT06006559 · 108 planned · Brazil, Colombia, India and more

Ahead

  1. Jul 22, 2027Primary completion: phase 2 study in DengueNCT06006559

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“NS4B inhibitor”the company's pipeline, read by Claude · source

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06006559Dengue · Brazil, Colombia, India and more2RecruitingJul 22, 2027108

How it is read

Names in the registry

  • “EYU688”, 1 entry

Codes read as this program: EYU688.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.